Combined embryotoxic action of toluene, a widely used industrial chemical, and acetylsalicylic acid (aspirin).
CFY rats were exposed to inhalation of fresh air at days 10-13 of gestation; at day 12 the dams were given 0, 125, 250, 500, or 1,000 mg/kg acetylsalicylic acid (ASA) by gavage. During the same period of gestation (days 10-13) further groups of rats were exposed to toluene at 1,000, 2,000, and 3,600 mg/m3 atmospheric concentration and were given 250 mg/kg ASA by gavage; two subgroups of animals treated with 250 mg/kg ASA in combination with 3,600 mg/m3 toluene inhalation were given 0, 2.5, or 5 gm/kg glycine 2 hours before the ASA dose. At day 21 the animals were killed and examined for teratogenic effects and histological changes. After 48 hours toluene exposure other groups of rats were treated with ASA or with ASA plus glycine (administered 2 hours earlier) on day 20 of gestation. These animals were killed 2 hours later and the salicylic acid concentration in maternal and embryonic plasma and in amniotic fluid was measured by gas chromatography. With the rising ASA doses both maternal toxicity (increased mortality, decreased food consumption, and weight gain) and embryonic toxicity (postimplantation loss, increased incidence of weight-retarded fetuses, increased minor anomalies and malformations, decreased average weight of fetuses) increased. Toluene was found to potentiate the toxic effect of ASA and to increase both maternal and embryonic toxicity. The type of ASA-induced minor anomalies and malformations was also found to be altered under the effect of toluene pretreatment. By raising the toluene concentration the salicylic acid level in the maternal and embryonic plasma and in the amniotic fluid was increased above the expected concentration. The mechanism of the potentiating interaction should be looked for in the depletion of the glycine pool by toluene (and its metabolites) and in the resultant increase of salicylic acid level. Increasing ASA embryotoxicity caused by toluene can be warded off by glycine administration.
D000014:Abnormalities, Drug-Induced / Q000473:pathology; D000653:Amniotic Fluid / Q000378:metabolism; D000818:Animals; D001241:Aspirin / Q000633:toxicity*; D004347:Drug Interactions; D004622:Embryo, Mammalian / Q000187:drug effects; D005260:Female; D005865:Gestational Age; D005998:Glycine / Q000494:pharmacology; D011247:Pregnancy; D051381:Rats; D012459:Salicylates / Q000097:blood; D020156:Salicylic Acid; D013723:Teratogens; D014050:Toluene / Q000633:toxicity*
D012459:Salicylates; D013723:Teratogens; D014050:Toluene; D020156:Salicylic Acid; D001241:Aspirin; D005998:Glycine